Vaccines for children and adults with chronic lung disease: Efficacy against acute exacerbations

Kerry-Ann O'Grady, Anne Chang, Keith Grimwood

    Research output: Contribution to journalArticle

    Abstract

    Acute exacerbations of chronic lung disease are usually associated with viral and bacterial pathogens. They contribute to declining lung function, poor quality of life and exert an excess burden on individuals, families, communities and the healthcare sector. Hence, preventing exacerbations is important in clinical management. Several vaccines providing protection against respiratory pathogens (Streptococcus pneumoniae, Bordetella pertussis and influenza) that can trigger exacerbations are available, but evidence to support their effectiveness in preventing exacerbations of chronic lung disease is limited. Candidate vaccines in pre-clinical or clinical development phases include those targeting Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, Pseudomonas aeruginosa, respiratory syncytial virus and human rhinoviruses. However, it is likely to be several years before vaccines against these pathogens are available for children and adults with chronic lung diseases. For vaccination to play an important role in managing chronic lung disease efforts need to be directed at understanding how various pathogens cause exacerbations and alter long-term lung function.
    Original languageEnglish
    Pages (from-to)43-55
    Number of pages13
    JournalExpert Review of Respiratory Medicine
    Volume8
    Issue number1
    DOIs
    Publication statusPublished - 2014

    Fingerprint Dive into the research topics of 'Vaccines for children and adults with chronic lung disease: Efficacy against acute exacerbations'. Together they form a unique fingerprint.

    Cite this